JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng
{"title":"Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.","authors":"JingSi Jiang, XiaoGang Li, YuXin Mi, YiYing Wang, YanXi Heng, ZhiWen Li, Min Deng","doi":"10.1080/17582024.2025.2488235","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).</p><p><strong>Patients & methods: </strong>Propensity score matching was used to balance baseline variables between the riluzole group (<i>n</i> = 238) and control group (<i>n</i> = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.</p><p><strong>Results: </strong>Riluzole did not significantly improve survival (<i>p</i> = 0.478) or ALSFRS changes at 6 months (<i>p</i> = 0.380) or 12 months (<i>p</i> = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.</p><p><strong>Conclusions: </strong>Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17582024.2025.2488235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS).
Patients & methods: Propensity score matching was used to balance baseline variables between the riluzole group (n = 238) and control group (n = 454). Survival was analyzed using Kaplan - Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders.
Results: Riluzole did not significantly improve survival (p = 0.478) or ALSFRS changes at 6 months (p = 0.380) or 12 months (p = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores.
Conclusions: Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
